Escalation with overdose control for phase I drug‐combination trials
Authors:
- 30 April 2013
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 32 (25) , 4400-4412
Abstract
Dose finding for combined drugs has grown rapidly in oncology drug development. The escalation with overdose control (EWOC) method is a popular model-based dose-finding approach to single-agent phase I clinical trials. When two drugs are combined as a treatment, we propose a two-dimensional EWOC design for dose finding on the basis of a four-parameter logistic regression model. During trial conduct, we continuously update the posterior distribution of the maximum tolerated dose (MTD) combination to find the most appropriate dose combination for each cohort of patients. The probability that the next assigned dose combination exceeds the MTD combination can be controlled by a feasibility bound, which is based on a prespecified quantile level of the MTD distribution such as to reduce the possibility of overdosing. We determine dose escalation, de-escalation, or staying at the same doses by searching the MTD combination along the rows and columns in a two-drug combination matrix, respectively. We conduct simulation studies to examine the performance of the two-dimensional EWOC design under various practical scenarios, and illustrate it with a trial example. Copyright © 2013 John Wiley & Sons, Ltd.Keywords
This publication has 18 references indexed in Scilit:
- Continual Reassessment Method for Partial OrderingBiometrics, 2011
- Dose‐finding approach for dose escalation with overdose control considering incomplete observationsStatistics in Medicine, 2011
- Utility‐Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II TrialsBiometrics, 2010
- Unifying CRM and EWOC designs for phase I cancer clinical trialsJournal of Statistical Planning and Inference, 2009
- A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple MyelomaClinical Cancer Research, 2009
- Bayesian Dose Finding in Oncology For Drug Combinations by Copula RegressionJournal of the Royal Statistical Society Series C: Applied Statistics, 2009
- A Parallel Phase I/II Clinical Trial Design for Combination TherapiesBiometrics, 2006
- Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose controlStatistics in Medicine, 2005
- Designs for Single‐ or Multiple‐Agent Phase I TrialsBiometrics, 2004
- Patient specific dosing in a cancer phase I clinical trialStatistics in Medicine, 2001